Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacopeia and Cephalon forge drug discovery pact
The primary objective of the alliance is to identify active molecules and bring them forward to clinical proof of concept, yielding novel candidates for drug development in various
The primary objective of the alliance is to identify active molecules and bring them forward to clinical proof of concept, yielding novel candidates for drug development in various
Alamo's sales force is currently marketing FazaClo (clozapine, USP), the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately
Treatment-resistant depression (TRD) is a condition in which some people with major depressive disorder (MDD) fail to sustain or achieve remission despite adequate antidepressant therapy. Conservative estimates indicate
The company plans to combine the probes with its proprietary signal amplification technologies, which will enhance their effectiveness by allowing visualization at levels not achievable by other methods.
The outcome of this trial is anticipated to support a supplemental new drug application (sNDA), which the company hopes to file with the FDA in the second quarter
The preliminary recommendations from the National Institute for Health and Clinical Excellence (NICE), the body that provides guidance to the UK National Health Service, looked at the aromatase
The studies, named PROVE 1 and PROVE 2, will be conducted in the US and Europe as part of a global phase II development program for VX-950. Together,
Rylomine is a patient-controlled nasal spray that delivers a single, metered dose of morphine, an opioid analgesic used for the treatment of moderate-to-severe pain. After use, a negligible
According to Dov an unusually high placebo response rate was the single major contributory factor to the failure of the trial. The company also said that the severity
This is the first study to identify a potential treatment option for patients who suffer from this variation of irritable bowel syndrome (IBS). The findings were presented at